IMNM Immunome, Inc.

NASDAQ
$17.61

Immunome, Inc. (IMNM) is expected to report earnings on February 8, 2027, after the market close. The consensus earnings estimate is a loss of $0.76 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on November 9, 2026.

Immunome Missed Consensus Estimates
Monday, November 9, 2026 · 4:02 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.76)
Rev est $2M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $18.49

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immunome, Inc.

Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.